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The immediate-early protein IE1 of human and mouse cytomegalovirus (MCMV) is one of the first proteins
expressed during the productive infection cycle and upon reactivation from latency. The CMV IE1 proteins
have been found to inhibit histone deacetylases, suggesting a role in the epigenetic regulation of viral gene
expression. Consequently, the IE1 protein is considered to have a profound effect on reactivation, because small
amounts of IE1 may be decisive for the switch to lytic replication. Here we asked if an MCMV ie1 mutant is
able both to establish latency and to reactivate from the lungs of latently infected mice. Since the ie1 mutant
was known to be attenuated during acute infection, we first defined conditions that led to comparable levels of
viral genomes during latent infection with mutant and wild-type (wt) MCMV. Viral genome copy numbers
dropped considerably at the onset of the latent infection but then remained steady for both viruses even after
several months. Reactivation of the ie1 mutant and of wt MCMV from latency occurred with similar
incidences in lung explant cultures at 4, 7, and 12 months postinfection. The increase in the frequency of a
subset of MCMV-specific memory T cells, a possible indicator of frequent transcriptional reactivation events
during latency, was in a comparable range for both viruses. Recurrence of the ie1 virus infection in vivo could
also be induced by hematoablative treatment of latently infected mice. We conclude that the ie1 gene is not
essential for the establishment of latency or for the reactivation of MCMV.
Infection with cytomegalovirus (CMV) is relatively common
in humans but is rarely diagnosed, because the primary infec-
tion is usually asymptomatic or presents with only mild symp-
toms (35). After clearance of the primary infection by the
immune system, a latent infection characterized by the absence
of detectable infectious virus is established in infected individ-
uals. The latent virus genomes persist in certain cell types, such
as monocytes or endothelial cells, in many organs of the host
(reviewed in references 21 and 47). The CMV infection may
occasionally recur from this state of dormancy, but usually it
remains undetected in healthy individuals, because the infec-
tion is rapidly controlled again by the immune system. Cellular
immunity, in particular the cytotoxic T-cell response, has been
recognized as crucial in the control of CMV replication and
disease as well as for the prevention of reactivation (9, 40, 42).
In immunocompromised patients, such as solid-organ or bone
marrow transplant recipients, reactivation from latency can
lead to high levels of CMV replication due to insufficient im-
mune control (reviewed in reference 5). CMV recurrence in
these patients is often associated with life-threatening disease;
one severe complication is interstitial pneumonia, which is
hard to control by medication and can be fatal.
The viral and cellular mechanisms that regulate the mainte-
nance of the viral genome during latency and those that trigger
reactivation are not well understood (for a review, see refer-
ence 53). In latently infected monocytes, the CMV genome has
been found as an episome (4), in accordance with the latent
state of other herpesviruses. CMV gene expression during la-
tency is severely restricted; a few transcripts have recently been
detected (3, 12, 22), but their significance is not yet known. It
is generally believed that reactivation is initiated by transcrip-
tional activation of the CMV major immediate-early (IE)
genes (53). Various stimuli can activate cellular transcription
factors, which then bind to the major immediate-early pro-
moter just upstream of the coding region for the IE proteins.
Studies with mouse CMV (MCMV), a widely used model for
the analysis of CMV latency and reactivation (reviewed in
references 19, 44, and 45), have indicated that cytokines asso-
ciated with infections or allorejection are such stimuli (8, 20,
50). Interestingly, the signaling events triggered by cytokines
do not necessarily result in the recurrence of MCMV infection;
usually, they lead only to the synthesis of major IE transcripts,
suggesting that additional processes are required (for instance,
differentiation of the latently infected cells into a permissive
state). Stochastic transcription events resulting in the genera-
tion of MCMV ie1 and ie2 transcripts have also been observed
during latency (14, 27).
The transcription units encoding the major IE proteins of
MCMV and human CMV (HCMV) display remarkable gene
structure similarity (7, 32). The primary transcript is differen-
tially spliced to generate two predominant mRNAs. One
mRNA consists of exons 1 to 4, and the other is composed of
exons 1 to 3 and 5. In HCMV, these mRNAs give rise to the
IE1 p72 and IE2 p86 proteins, while the corresponding IE
mRNAs of MCMV encode the 89-kDa IE1 phosphoprotein
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(25) and the 88-kDa IE3 protein (33). HCMV IE2 and MCMV
IE3 serve as transactivator proteins, which are required for the
transcriptional activation of viral genes expressed later in the
productive infection cycle. The CMV IE1 proteins were ini-
tially characterized as regulatory coactivator proteins that sup-
port the transactivating function of the IE2 or IE3 protein (52).
One prominent role that was reported for the IE1 proteins of
both CMVs is the disruption of subnuclear structures called
promyelocytic leukemia protein-associated nuclear bodies
(PML NBs), or ND10 domains (1, 26, 63). These structures are
characterized by the accumulation of several cellular proteins,
such as Sp100, hDaxx, and PML, the latter being required for
the formation of PML NBs. They are believed to play a role in
the intrinsic antiviral defense of cells, since viral genomes en-
tering the nuclei of infected cells are localized and possibly
sequestered at or next to PML NBs (reviewed in reference 30).
The antiviral function may be mediated via the PML protein
(57, 58), which represses transcription by interacting with his-
tone deacetylases (64), or via the Sp100 protein, which binds to
the heterochromatin protein HP1, involved in transcriptional
silencing (29). Thus, the IE1 protein seems to be required by
the virus to counteract the antiviral function of PML NBs,
thereby supporting the initiation of the productive infection
cycle.
A direct interaction between the MCMV IE1 protein and
the histone deacetylase HDAC2 has been described. This in-
teraction results in reduced histone deacetylase activity (55),
possibly facilitating the formation of an open chromatin struc-
ture of the viral genome. Similarly, an interaction between
HDAC3 and the HCMV IE1 protein has been found (37).
Consistent with an activity of the IE1 protein in epigenetic
regulation of CMV gene expression, HCMV ie1 deletion mu-
tants display a severe growth defect at a low multiplicity of
infection (MOI) in cell culture (13, 34). In contrast to the
HCMV mutant, an MCMV ie1 deletion mutant grew with
kinetics comparable to those of wild-type (wt) MCMV in var-
ious cell types in vitro, independently of whether infection was
performed at a low or a high MOI (10). In vivo, the ie1
mutant displayed an attenuated phenotype (10); the doubling
time of the viral titers was significantly reduced in various
organs, including the lungs (62).
Although an important role for the IE1 protein during latent
infection or in reactivation has frequently been suggested, this
concept has not been experimentally tested. In this study, we
asked whether the MCMV ie1 gene plays a role in regulating
the establishment of latency, in the maintenance of the latent
genomes, or in the reactivation of MCMV from the lungs of
latently infected mice. Unexpectedly, we found that a ie1
mutant is able to reactivate from latency in explanted lung
tissue in vitro as well as in vivo with an incidence similar to that
for wt MCMV.
MATERIALS AND METHODS
Viruses. The generation of the bacterial artificial chromosome-derived
MCMV strain MW97.01 (59) and of the ie1 mutant (10) has been described
previously. Strain MW97.01 has been shown to be as virulent as the MCMV
Smith strain (59) and was designated wt MCMV in this study. The viruses were
propagated on primary mouse embryonic fibroblasts (MEF), which were pre-
pared from the embryos of pregnant BALB/c mice on day 17 of gestation. Virus
stocks were produced as described previously (6).
MCMV infection of mice. Newborn female BALB/c mice (Charles River,
Sulzfeld, Germany) were intraperitoneally infected 4 days postnatum with dif-
ferent doses of the MCMV strains in 50 l of phosphate-buffered saline. Mice
were housed in ventilated cages in an area otherwise free of murine pathogens
as revealed by microbiological monitoring according to FELASA recommenda-
tions (38). At designated times after infection, mice were sacrificed, and organs
were excised and homogenized by passing through a 0.55-mm wire mesh (Roth,
Karlsruhe, Germany) prior to further processing. Animal experiments were
approved under permission numbers 33-42502-05/1058 and 33.9-42502-04-07/
1336 according to German federal law.
Quantification of infectious virus. Virus titers were determined by a plaque
assay performed on subconfluent second-passage MEF monolayers in triplicate.
Centrifugal enhancement at 500  g was applied for 30 min, followed by 2 h of
incubation at 37°C. The inocula were then replaced by 500 l of 0.75% (wt/vol)
carboxymethylcellulose (Sigma-Aldrich, Schnelldorf, Germany) in growth me-
dium per well. On day 5 postinfection (p.i.), plaques were counted, and viral
titers per whole organ were calculated.
Quantification of viral genomes. Ten percent of the lung homogenates was
used to extract genomic DNA (DNeasy blood and tissue kit; Qiagen), and 100 ng
of extracted DNA was subjected to quantitative real-time PCR, performed as
described previously (50). Plasmid pDrive_gB_PTHrP_Tdy was used to generate
a standard curve in order to calculate the ratio of viral to mouse genomic DNA.
PCR was performed in a final volume of 25 l of Brilliant SYBR green mix
(Stratagene, Amsterdam, The Netherlands) on an Mx3000P cycler (Stratagene).
Quantification of MCMV-specific T cells. Splenocytes were isolated from
latently infected BALB/c mice. P815 mastocytoma cells (ATCC TIB-64) were
pulsed for 2 h at 37°C with synthetic peptides 168-YPHFMPTNL-176 of the IE1
protein (16) and 257-AGPPRYSRI-265 of the m164 protein (17) (Eurogentec,
Liege, Belgium) at 108 M, and then 105 splenocytes were coincubated with 105
of the peptide-loaded P815 cells for 20 h. Gamma interferon (IFN-)-producing
cells were quantified by an enzyme-linked immunospot (ELISPOT) assay (eBio-
science, San Diego, CA) according to the manufacturer’s instructions. The
Mann-Whitney statistical test (non-Gaussian) provided with the GraphPad Prism
5 program (GraphPad, La Jolla, CA) was used to compare the T-cell frequencies
between different mouse groups. Differences were considered to be significant if
the P value of the two-tailed test was 0.05.
Ex vivo reactivation assay. Lungs were isolated from latently infected BALB/c
mice and cut into small pieces with scissors. The pieces from one lung were
randomly distributed into the wells of a 6- or 12-well plate, and the cultures were
maintained in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum and antibiotics. The medium was replaced twice a week, and
supernatants were harvested over 6 weeks to monitor for the presence of infec-
tiousvirusbytransfertoMEFindicatorcells.Thecultureswereanalyzedmicroscopi-
cally for the occurrence of cytopathic effects 1 week posttransfer. NIH 3T3 cells
infected with the recovered viruses were analyzed by immunoblotting using
monoclonal antibodies Croma101 (anti-IE1 [IE1]) and Croma103 (E1) (both
kindly provided by Stipan Jonjic´, Rijeka, Croatia) and a secondary horseradish
peroxidase-conjugated anti-mouse antibody (Dako, Hamburg, Germany). Sig-
nals were visualized with an ECL detection reagent (GE Healthcare, Munich,
Germany) on a LAS3000 imager (Fuji, Du¨sseldorf, Germany).
In vivo reactivation. Hematoablative treatment of latently infected BALB/c
mice was performed by total-body irradiation with a single sublethal dose of 6.5
Gy within 12 min using a Siemens Mevatron MX-2 system (Erlangen, Germany).
For the following 8 days, mice were treated with the antibiotic cotrimoxazole
(240 mg per liter of drinking water [Ratiopharm, Ulm, Germany]). Mice were
sacrificed; the lungs were excised and homogenized; and the amounts of viral
genomes and infectious virus were analyzed by PCR and plaque assay, respec-
tively. The DNA of reactivated viruses was further analyzed by PCR using
primers 5	-CCTCACTCTCAGAGGGCTTATGTAA-3	 and 5	-TTTAGAGAG
ATGGAGCCCGC-3	, giving rise to a 2,465-bp product for wt MCMV and a
609-bp product for the ie1 virus.
RESULTS
Growth of the ie1 mutant in the lungs of infected mice and
establishment of latency. Previous studies have shown that the
lungs are a major site of MCMV latency and recurrence (2)
and that infection of newborn mice results in a high viral
genome load in the lungs (43). The viral load, in turn, defines
the likelihood of the recurrence of MCMV infection (43). The
newborn infection model seemed to us, therefore, to be highly
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suitable for evaluating the reactivation capacity of the ie1
mutant in the lungs. Our first aim was to define infection
conditions that resulted in similar multiplication of the ie1
mutant and of wt MCMV in the lungs, because this was found
to be a requirement for the establishment of a comparable viral
genome load during latency (43). The ie1 mutant was previ-
ously analyzed with adult mice, and attenuation was observed
(10). Therefore, we first investigated the growth of the ie1
mutant, in comparison to the growth of the wt virus, in the
lungs of infected neonatal mice. Newborn BALB/c mice were
infected intraperitoneally with different doses of the viruses,
and virus titers in the lungs were measured at 3 and 12 days p.i.
(Fig. 1). Based on previous data regarding the susceptibility of
newborn mice to MCMV (15, 43) and the expected attenuation
of the mutant (10), we used infection doses of 100 and 500
PFU of the wt virus and 103, 104, and 105 PFU of the ie1
mutant. Infection with 500 PFU of the wt virus was lethal for
two of six mice within 12 days, underlining the susceptibility of
newborn mice to MCMV. At day 3 p.i., 103 PFU of the ie1
mutant resulted in titers in the lungs comparable to those
resulting from 500 PFU of wt MCMV (Fig. 1A), but on day
12 p.i., titers in ie1-infected mice were
1 order of magnitude
lower than those in mice infected with 100 or 500 PFU of wt
MCMV (Fig. 1B). Infection with 104 PFU of the ie1 mutant
led to higher titers at both time points than the highest dose
(500 PFU) tested for wt MCMV. At 105 PFU of the ie1 virus,
five of six mice succumbed to infection within 12 days. Since it
was difficult to find inoculation doses that led to comparable
titers of the two viruses in the lungs at both time points, we
decided to start our experiments with a nonlethal dose of 100
PFU for the wt virus and with 103 PFU of the ie1 mutant.
This may result in higher titers for the mutant initially and in
higher titers for the wt virus at later times. The intention,
however, was to achieve similar loads of viral genomes during
latency, since we considered this a precondition for comparing
the reactivation capacities of the mutant and the wt virus. Six
months after infection with 100 PFU of wt MCMV or 1,000
PFU of ie1, the loads of latent viral genomes in the lungs
were determined by quantitative PCR. For both viruses, ge-
nome loads in the range of 103 viral genomes per 106 lung cells
were found (Fig. 1C). In conclusion, we were able to establish
infection conditions that resulted in similar loads of latent viral
genomes in the lungs, thereby allowing us to study the role of
the IE1 protein in latency and reactivation without any bias
resulting from the attenuation of the ie1 mutant in the acute
infection phase.
Reactivation of the ie1 mutant in lung explant cultures.
Four months p.i., infectious virus was no longer detectable in
the lungs of infected animals (see, e.g., Fig. 5B), indicating that
a latent infection had been established. We chose lung explant
cultures as described by Presti et al. (41) to study the reacti-
vation of the ie1 mutant. The recurrence of infectious
MCMV in the cultures was monitored for 42 days. Starting at
2 weeks after explantation, infectious virus was found in the
supernatants of the cultures. Altogether, the lung explant cul-
tures from four of six mice infected with the ie1 mutant and
from five of six mice infected with wt MCMV gave rise to
reactivated virus (Fig. 2A). In addition, we did not see an
obvious difference in the kinetics of reactivation of the two
viruses (data not shown). To verify that the viruses recovered
from the lung explant cultures were identical to the viruses
used for infection of the mice, the reactivated viruses were
grown on fibroblasts, and the synthesis of the IE1 and E1
proteins was analyzed (Fig. 2B). These results demonstrated
that the ie1 mutant is able to establish latency and that the
IE1 protein is dispensable for the reactivation of MCMV in
explanted lung tissues.
Time course of the viral genome loads in the lungs. To
analyze whether the IE1 protein may have a role in the main-
tenance of the viral genome load during extended periods of
FIG. 1. Growth of the ie1 mutant and viral loads established in the lungs of infected BALB/c mice. Groups of six female newborn BALB/c
mice were intraperitoneally infected with the indicated doses of wt MCMV () or the ie1 mutant (f). Viral titers in the lungs were quantified
3 (A) and 12 (B) days (d) p.i. Each data point represents the titer for an individual animal, and the horizontal bars indicate the medians for each
group. The detection limit is indicated by the dashed lines. (C) Viral genome loads in the lungs of latently infected mice were measured 6 months
after infection with 100 PFU of wt MCMV () or 1,000 PFU of the ie1 mutant (f). The medians are indicated by horizontal bars.
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latency, we infected newborn BALB/c mice and determined
the genome loads in the lungs by quantitative PCR at different
time points p.i. It is known that the viral genome copy numbers
in the organs of infected mice drop considerably when the
acute infection is cleared and the latent infection is established
(11). In view of the sensitivity of the quantitative PCR and the
need to detect a potential decline in the viral genome load
during latency, we aimed to start with the maximal possible
genome load at the onset of latent infection. To this end, we
infected the mice with 104 PFU of the ie1 mutant or 100 PFU
of wt MCMV. Under these conditions, a slightly higher ge-
nome load was detected for the ie1 mutant than for wt
MCMV in the acute infection phase at 1 week p.i. (Fig. 3).
During the following 2 weeks, the genome copy numbers de-
creased rapidly by approximately 1 (wt MCMV) or almost 2
(ie1 mutant) orders of magnitude. Thereafter, however, the
loads of both viruses were found to be maintained at this level
until 28 weeks p.i. This finding showed that although there was
a more pronounced reduction of genome copy numbers of the
ie1 mutant in the lungs around the time point when latency
was established in the lungs, no further decline in the load of
the ie1 mutant in the subsequent latency phase was observed
in comparison to the load of wt MCMV, indicating that the IE1
protein is not essential for the maintenance of the MCMV
genome during latency.
Expansion of m164-specific T cells after infection with the
ie1 mutant. The majority of the MCMV-specific memory T
cells in the chronic phase of infection are specific for only a few
viral epitopes, and the frequency of these memory T cells in-
creases over time (16, 17, 24, 36). While the mechanism driving
this process, termed memory inflation, has not yet been clearly
defined, a plausible explanation is the frequent and stochastic
recurrence of viral gene expression during latency, leading to
T-cell restimulation and expansion (reviewed in references 45 and
60). If the IE1 protein is involved in the opening of the viral
chromatin structure or in the maintenance of the open structure,
one might expect that the ie1 mutant would switch on viral
protein expression less frequently or to a lower extent and that
therefore the accumulation of immunodominant memory T cells
would be less prominent. Thus, we considered it worthwhile to
measure the frequency of these MCMV-specific T cells at 7 and
12 months p.i. The proportion of T cells responding with IFN-
production upon restimulation with the immunodominant m164
and IE1 peptides was determined by an ELISPOT assay (Fig. 4).
Splenocytes of mice latently infected with wt MCMV responded
to both peptides, while infection with the ie1 mutant failed to
FIG. 2. Ex vivo reactivation of the ie1 mutant. (A) Groups of six
mice were infected with either 102 PFU of wt MCMV (hatched bar) or
103 PFU of the ie1 mutant (open bar). Four months p.i., lungs of
latently infected mice were explanted, and reactivation of the viruses in
the explant cultures was monitored for 42 days. (B) The identities of
the recovered viruses were verified by immunoblot analysis with mono-
clonal antibodies directed against the IE1 (top) or the E1 (m112/113)
(bottom) protein. Lysates were obtained from cells infected with the
viruses recovered from wt or ie1 MCMV-infected mice (lanes 1 and
2, respectively) and, for comparison, from cells infected with wt or ie1
MCMV (lanes 3 and 4, respectively). (C) Groups of four to seven mice
were infected with either 102 PFU of wt MCMV (hatched bars) or 104
PFU of the ie1 mutant (open bars). At 4, 7, and 12 months p.i.,
explant cultures of lung tissues were established, and the reactivation
incidence was determined as described for panel A.
FIG. 3. Time course of viral genome loads in the lungs. Viral ge-
nome copy numbers were measured by quantitative PCR at the indi-
cated time points after infection of newborn BALB/c mice with either
102 PFU of wt MCMV () or 104 PFU of the ie1 mutant (f). The
median values are represented by horizontal bars, and the detection
limit is indicated by dashed lines.
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induce IE1-specific T cells, due to the absence of the IE1 protein
(10). This sample, therefore, served as an additional control for
the specificity of the assay. m164-specific T cells were present at
the same frequency in mice infected with either of the viruses at
7 months p.i. (Fig. 4A). At 12 months p.i., the frequencies of these
T cells showed larger differences between individual mice than at
7 months p.i., and the median frequency of the IE1-specific T cells
in the wt MCMV-infected mice was doubled. The increases in the
median frequencies of the m164-specific T cells were less prom-
inent (1.37- and 1.46-fold) than the increase in the median fre-
quency of the IE1-specific T cells. Most importantly, the frequen-
cies of the m164-specific T cells were in a similar range in theie1
and wt virus-infected mice at 12 months p.i., and there was no
statistically significant difference. We interpret our findings as a
hint that transcriptional reactivation of viral protein expression in
vivo does not depend critically on the ie1 function.
The lung tissues of the mice for which the T-cell frequencies
were determined and those of another group of mice infected
under the same conditions were explanted, and the incidence
of reactivation in the cultures was investigated (Fig. 2C). At 4
and 7 months p.i., reactivation occurred in the lung tissues of
all of the mice and of four of five mice infected with either the
wt or the ie1 virus, respectively, and at 12 months p.i., reac-
tivation occurred in the lung tissues of six of seven mice in-
fected with the ie1 mutant and three of seven mice infected
with wt MCMV. The reactivation incidences were also calcu-
lated based on the numbers of reactivation events observed in
individual wells containing the lung pieces. When individual
cultures of lung pieces explanted at 4 months p.i. were ana-
lyzed, the reactivation incidence was found to be high (70%)
and almost identical for the wt virus and the ie1 mutant (data
not shown). At later time points, the reactivation incidence was
much lower (10 to 40%), suggesting that fewer of the latent
virus genomes were capable of reactivating then. At 4 and 12
months p.i., reactivation occurred in more of the cultures con-
taining lung pieces from ie1 mutant-infected mice than of the
cultures with lung pieces from wt MCMV-infected mice. This
was most likely due to a slightly higher genome load in the
lungs of mice infected with the ie1 mutant (compare, e.g.,
Fig. 5A). Altogether, these results confirmed that the ie1 gene
is not needed for reactivation.
Induced reactivation of the ie1 mutant in vivo. The latent
infection is controlled by cellular immunity, and accordingly, re-
currence of the MCMV infection is observed after ablation of
immune cells by irradiation (46). To test whether the ie1 mutant
has the capacity to reactivate in vivo, infected mice were treated
with hematoablative irradiation 4 months after infection. As an
indicator of reactivation, we measured the increase in the viral
genome copy number in the lungs 8 days after irradiation and
compared these data to those for nonirradiated mice (Fig. 5A).
Prior to irradiation, the copy number of latent viral genomes in
infected lungs was slightly higher for the ie1 mutant than for wt
MCMV in this experiment. Following irradiation, the medians of
the copy number of viral genomes increased similarly for both
viruses (11-fold for wt MCMV and 8-fold for the ie1 mutant).
We also analyzed whether infectious virus was detectable in irra-
diated and nonirradiated mice. For the untreated mice, no virus
was found in the lungs (Fig. 5B), as expected for a truly latent
infection. However, after irradiation, infectious virus was present
in the lungs of two of five mice infected with the ie1 mutant and
of four of five mice infected with wt MCMV. The identities of the
recovered viruses were verified by PCR analysis (Fig. 5C). These
experiments indicated that following hematoablative treatment of
latently infected mice, MCMV is able to reactivate in vivo in the
absence of the IE1 protein.
DISCUSSION
A detailed understanding of the molecular mechanisms of
CMV reactivation is crucial for the development of specific
therapeutic intervention strategies. In this study, we focused
on the role of the ie1 gene in regulating the latency and reac-
FIG. 4. Frequency of MCMV-specific T cells. Mice were infected
with wt MCMV (open symbols) or the ie1 mutant (filled symbols) as
described in the legend to Fig. 3, and splenocytes were isolated 7
(A) and 12 (B) months p.i. IFN--producing T cells were detected by
an ELISPOT assay after restimulation with the immunodominant
peptide of the IE1 (circles) or m164 (squares) protein or after
treatment without peptides (diamonds). Medians are indicated by
horizontal bars.
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tivation of MCMV in vivo. Although the ie1 mutant turned
out to be attenuated in acute infection of newborn mice, it was
able to establish a latent infection, and up to 12 months p.i. its
reactivation capacity, as determined in lung explant cultures,
was similar to that of wt MCMV. The load of viral genomes in
the lungs remained unchanged between 3 weeks and 7 months
p.i., as was the case for wt MCMV, suggesting that the ie1 gene
is also not required for the maintenance of the viral genomes
during latency. Similarly, the ie1 mutant reactivated in vivo
after hematoablative irradiation, and the increase in number of
a subset of MCMV-specific memory T cells, which may provide
an indirect measurement of reactivation events in vivo, was in
the same range for ie1 mutant- and wt MCMV-infected mice.
We conclude from these investigations that the ie1 gene is not
essential for maintaining latency or for regulating the reacti-
vation of MCMV.
Acute infection, establishment of latency, maintenance of
the latent viral genomes, and reactivation are interconnected
and interdependent phases of CMV infection. Accordingly, the
extent of the primary CMV infection determines the number
of viral genomes present in latency, and this in turn influences
the risk of reactivation (43). Thus, to analyze the reactivation
capacity of the ie1 mutant, it was necessary to consider the
preceding phases of infection. As expected from our previous
study (10), the ie1 mutant was found to be attenuated in
comparison to the wt MCMV during acute infection of new-
born mice. The cause of this attenuation was not the focus of
this investigation, but our data and the observations of another
group, who found that the doubling time for the titers of the
ie1 mutant was significantly delayed in several organs of ir-
radiated mice, including the lungs (62), are consistent with our
previous suggestion (10) that the ie1 mutant displays in-
creased sensitivity to the innate defense mechanisms of the
host.
Infection with a nonlethal dose (100 PFU) of wt MCMV and
a 10-fold higher dose of the ie1 mutant led to comparable
viral loads in the lungs during latency. This result could not be
anticipated, since the acute infections did not proceed synchro-
nously for the two viruses. While the titers of the ie1 mutant
at day 3 p.i. were higher than those of wt MCMV, the infection
with the mutant was more rapidly controlled thereafter. It can
be assumed that the virus has to attain high titers during acute
infection in order to establish latency, possibly in rare cellular
niches that may not be permissive for lytic replication. The
decline in the number of viral genomes observed between
acute and latent infection was more pronounced for the ie1
mutant than for the wt virus; this could be due to a reduced
ability of the ie1 mutant to establish latency or, alternatively,
to a saturation of the available cells supporting latency. The
conclusion that we wish to draw, however, is that the ie1
mutant is still capable of establishing latency.
The MCMV ie1 gene did not seem to be required for the
maintenance of latent viral genomes, since the genome copy
number did not decline during latency. This conclusion is also
supported by the observation that the ie1 mutant reactivated
with an incidence similar to that of the wt virus at different time
points during latency. At this time, we know very little about
the mechanisms that govern the maintenance of the latent
genomes. One possibility is the frequent recurrence of produc-
tive CMV infection, which would guarantee the replenishment
of the pool of latently infected cells. Alternatively, the CMV
genomes may be amplified and segregated during cell division
of the latently infected cells, a mechanism employed mainly by
gammaherpesviruses. In both cases, a change in the epigenetic
modification of the chromatin structure of the viral genomes is
FIG. 5. In vivo reactivation of the ie1 mutant in the lungs of irradiated
mice. (A) Four months after infection with 102 PFU of wt MCMV or 104
PFU of the ie1 mutant, mice were either irradiated (irr.) () or left un-
treated (). Reactivation in the lungs was measured by an increase in the viral
genome load (shaded areas). The genome loads of wt MCMV () and of the
ie1 mutant (f) per 106 lung cells are shown. Median values are indicated by
horizontal bars. (B) The presence of infectious virus in the lungs of untreated
or irradiated mice was analyzed by homogenizing the lung tissue and plating
on fibroblast cultures. (C) PCR analysis was performed with DNA isolated
from fibroblasts infected with the viruses recovered from irradiated mice (as
shown in panel B) or from fibroblasts infected with the ie1 mutant and wt
MCMV as controls (co). The sizes of molecular mass markers (in kilobase
pairs) are given on the right.
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conceivable, and a role for the IE1 protein could have been
expected.
The presence of viral genomes does not necessarily imply
that a latent infection is established; it could also reflect an
abortive infection that will never be able to recur. Thus, we
analyzed the ability of the ie1 mutant to reactivate by apply-
ing three different techniques to address this question: analysis
of virus recovery from ex vivo lung explant cultures, monitoring
of the memory inflation of MCMV-specific T cells, and induc-
tion of reactivation in vivo. In the ex vivo reactivation experi-
ments, the ie1 mutant displayed a high incidence of reacti-
vation events at 4, 7, and 12 months p.i. It is clear that this assay
is associated with some inherent variability; for instance, we
observed fewer reactivation events for wt MCMV at 12 months
p.i. than at the other time points, even when individual lung
pieces were analyzed. We also have to consider that infection
with the ie1 mutant was performed with a 10- to 100-fold-
higher dose to compensate for the reduced replication capacity
of the mutant during acute infection. Infection with an identi-
cal inoculation dose would lead to a lower viral load of the ie1
mutant and consequently would result in a reduced reactiva-
tion incidence. Overall, however, the data suggest that the ie1
mutant is in principle able to establish latency, and when sim-
ilar loads of latent viral genomes are present in the lung tis-
sues, the mutant does not seem to be impaired in reactivation
in comparison to wt MCMV.
The factors that induce reactivation in the explant cultures
may include mechanical stress or hypoxia and may not neces-
sarily reflect the physiological stimuli that trigger reactivation
in vivo. Therefore, we also analyzed parameters that indicate in
vivo reactivation. The maintenance or even expansion of
CMV-specific memory T cells during the latent infection phase
could be explained by frequent reactivation of viral protein
expression in vivo, leading to the generation of antigens that
trigger the proliferation of T cells (16, 17, 24, 49, 51). We
therefore reasoned that analysis of the frequency of these T
cells may give us at least a hint as to whether the capacity of the
ie1 mutant for reactivation in vivo is altered. Since one of the
immunodominant epitopes of MCMV in BALB/c mice derived
from the IE1 protein is missing in the ie1 mutant, we focused
on the T cells that are specific for the other immunodominant
epitope, which originates from the m164 protein (17). Al-
though there was quite a variation in the number of m164-
specific T cells among individual mice at 12 months p.i., we did
not see a significant difference in the frequencies of these T
cells between ie1 mutant- and wt MCMV-infected mice. We
must point out that other mechanisms for the expansion of the
CMV-specific memory T cells have been proposed (54) and
that the exact mechanism for this phenomenon remains to be
elucidated. However, it is reasonable to assume that frequent
reactivation is the underlying principle that drives memory
inflation (45, 51, 60). If this is true, then our data suggest that
the ie1 mutant is not impaired in transcriptional reactivation
in vivo.
Finally, we analyzed the induced in vivo reactivation of the
ie1 mutant following ablation of the immune cells by irradi-
ation. This resembles the situation in immunocompromised
patients, e.g., in stem cell transplant recipients. After irradia-
tion, increased levels of viral genomes were found, and infec-
tious virus was recovered from the lungs of mice infected with
either virus, clearly demonstrating that the ie1 mutant can
reactivate in vivo. The increases in the viral genome loads after
irradiation were similar for the two viruses. Infectious virus
was, however, recovered in fewer mice infected with the ie1
mutant than with the wt virus. This may be interpreted as a
reduced reactivation capacity of the ie1 mutant, but it is
rather attributable to the limited sensitivity of the assay. It has
been shown previously that virus reactivation after irradiation
is a stochastic event and does not necessarily result in reacti-
vated virus in each organ (43). In addition, neutralizing anti-
bodies confine the reactivated virus to small foci where the
reactivation has occurred (23), and therefore it was not sur-
prising that we could detect small amounts of virus in the lungs
of some irradiated mice only. Further investigations to quantify
the reactivation capacity of the ie1 mutant in vivo may have
to be performed with mice lacking antibodies (40).
The salient result of our study, namely, that the ie1 mutant
is able to reactivate in explanted lung tissue and also in vivo,
was unexpected, since in a previous study the MCMV IE1
protein was clearly shown to interact with the histone deacety-
lase HDAC2 at an early stage of the lytic infection cycle in
vitro, and this interaction correlated with a marked reduction
in the deacetylation activity in infected cells (55). In addition,
the IE1 protein interacts with the repressor proteins PML and
Daxx and may inhibit their function, thus promoting the viral
gene expression program. This begs the question of why the
ie1 mutant showed no phenotype during reactivation, at a
stage of the CMV infection when the antiviral defense of the
latently infected cell must be overcome. One explanation is
that other viral proteins substitute for the regulatory function
of the IE1 protein. Experiments by Tang and Maul indicated
that IE1 is indeed not the sole MCMV protein that inhibits
HDAC activity (55). In HCMV, both IE1 and IE2 are able to
interact with HDAC3 (37). Thus, it is reasonable to assume
that the homolog of the HCMV IE2 protein in MCMV, the
IE3 protein, might possess a similar property, but this remains
to be examined. If IE3 inhibits histone deacetylases as well, this
would perfectly explain the compensation of the IE1 function.
An important question is whether the result that we ob-
tained for the MCMV ie1 gene can be extrapolated to the role
of the HCMV ie1 gene in the reactivation of HCMV. IE1
proteins of MCMV and HCMV share many functions, includ-
ing the ability to bind and to inhibit histone deacetylases and to
disperse proteins that are associated with PML NBs (reviewed
in references 7 and 31). Both IE1 proteins are multifunctional,
and the dissection of their various functions and their assign-
ment to different domains of the proteins have just begun (18,
28, 31, 48, 56, 62). Concerns have been raised about differences
in the functions of the major IE proteins of MCMV and
HCMV and hence about the validity of the MCMV model
(31). However, the recent finding that the MCMV IE3 protein
is able to arrest the cell cycle in infected cells, as is its HCMV
homolog, IE2 (61), underlines the fact that the CMV major IE
proteins have much more in common than previously antici-
pated. Another recently described property of the HCMV IE1
protein is its interaction with the signal transducer and activa-
tor of transcription STAT2, interfering with interferon signal-
ing and the activation of interferon-stimulated genes (18, 39).
It is not yet known whether the MCMV IE1 protein possesses
a similar role in combating the cellular innate immune re-
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sponse, but this would explain the observed attenuation of the
ie1 mutant in vivo (10, 62; also this study).
In summary, we were able to show that the function of the
MCMV ie1 gene is not critical for the maintenance of latency
or for reactivation. In order to learn more about the role of the
IE1 protein in the pathogenesis of CMV, we have to dissect the
different functions of the MCMV and HCMV IE1 proteins
more precisely. By constructing MCMV recombinants with
more subtle mutations in the ie1 gene, we can test further
hypotheses about the function of the IE1 protein in vivo.
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